Aktieanalys

InDex Pharmaceuticals: Discontinues development of cobitolimod - Redeye

{newsItem.title}

Redeye Publicerad: 27 Feb 2024 08:08

Redeye provides its comments on yesterday's news that InDex Pharmaceuticals discontinues the development of cobitolimod and will not proceed development of any of its other compounds.

Länk till analysen i sin helhet: https://www.redeye.se/research/986535/index-pharmaceuticals-discontinues-development-of-cobitolimod?utm_source=finwire&utm_medium=RSS

Nyheter om Flerie

Läses av andra just nu

Om aktien Flerie

Senaste nytt